Sanofi announces phase 3 study data for infantile-onset Pompe disease
Pompe disease is a rare, progressive neuromuscular disease, with infantile onset being the most aggressive form
- News
- Research
- Sales
- Regulatory
- Healthcare
- Marketing
Sanofi announces phase 3 study data for infantile-onset Pompe disease
Pompe disease is a rare, progressive neuromuscular disease, with infantile onset being the most aggressive form
Lilly to acquire LimmaTech Biologics and Vaccine Company in deals totalling $2.33bn
The acquisitions reinforce the company’s commitment to reduce the long-term burden of serious disease
Roche’s Enspryng given FDA Priority Review as thyroid eye disease treatment
This is the first and only at-home subcutaneous treatment option for this disease
Zymeworks to acquire Theravance Biopharma in deal worth $929m
The acquisition will give the company access to a treatment for COPD
PMEA welcome Simon Bates as new Chair of the judging panel
Roche and Alnylam share their experiences entering the PMEAs
Latest content
The outcomes economy: where next for pharma?
‘In the emerging framework, a medicine’s value will increasingly depend on how effectively care is delivered around it’
Read More
Candel Therapeutics appoints Mark Sims as Chief Commercial Officer
Sims previously held senior level roles at AstraZeneca, Novartis and Merck
Read More
MRM Health appoints Hans-Jürgen Wörle as Independent Director
Wörle previously held senior roles at Nestlé Health Science and Boehringer Ingelheim
Read More
MRM Health appoints Michel Detheux as Chairman of the Board
Detheux was previously founding CEO of iTeos Therapeutics
Read More
Intelligence
Achieving launch excellence through cross-functional collaboration
‘Cross-functional collaboration that’s grounded in a clear evidence roadmap is the foundation for successful, sustainable launches’
Read More
Steering generative AI into the pharma fast lane
Industry needs to press the accelerator to adopt AI across functions to
supercharge launch excellence
Bridging the gap between European brain innovation and real-world policy
Aligning policy and public funding strategies to support brain health across Europe
Read More
Obesity care in the UK – why it can’t improve until it is recognised as a disease
The WHO classified obesity as a chronic disease over twenty years ago – but UK policy has yet to follow
Read More
The next frontier in clinical trials: navigating multi-disease research with GLP-1s
As GLP-1s redefine the treatment landscape for obesity, they are also promising candidates to influence a wide range of disease pathways
Read More
Headline trade and market deals are opening doors to greater patient access
Regulatory changes and tariffs have created a positive climate for investment, innovation and, critically, patient access to therapies
Read More
Blogs
Latest
Women in Healthcare Leadership Have a Lot to Say. Medscape’s Hear From Her Wins an APEX Grand Award.
July 2, 2026 | Medscape Education|#APEX2026
Medscape Education has been honoured with the prestigious APEX Grand Award for Publication Excellence at…
Moving Beyond the 10%: A New Era in Preterm Birth Prevention
July 1, 2026 | Medscape Education|#HearFromHer #PretermBirth
For decades, the rate of spontaneous preterm birth in the United States has hovered stubbornly around 10%. Despite advancements in other areas of medicine, prematurity …
Supporting our team with an award-winning mental health strategy
June 26, 2026 | Mednet|Making Health Whole, Mental Health Awareness, Mental Health Strategy
Mental health has been at the centre of our business since our inception. But that work doesn’t just extend to our client projects. Find out …
Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026
June 24, 2026 | Genesis Research Group|AI, HEOR, Market Access, RWE, evidence, evidence synthesis, genesis, literature reviews, slr
Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations …
Medscape Education to Showcase the Impact of Neurology CME at EAN 2026
June 23, 2026 | Medscape Education|
Medscape Education, the leading global provider of continuing medical education (CME), has announced its agenda for the upcoming 12th Congress of the European Academy of …
5 key takeaways from the Patient Centricity and Engagement Conference
July 2, 2026 | Cuttsy + Cuttsy|Patient-centricity, patient engagement
Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful partnership can help turn patient engagement from intention into action.
It’s time to stop calling adverse events ‘manageable’
June 29, 2026 | Cuttsy + Cuttsy|Adverse effects, Manageable toxicity, clinical trial, patient engagement, patient experience
A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication reflected patients’ lived experience more clearly.
The value: why localisation pays off across global trials
June 26, 2026 | Cuttsy + Cuttsy|Localisation, clinical trials, translation
Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies run more smoothly, fairly and efficiently.
Live Webinar | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026
June 18, 2026 | Inizio|
Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.
The solution: Good localisation doesn’t feel translated
June 18, 2026 | Cuttsy + Cuttsy|Engagement, Inclusion, Localisation, Trusted information, clinical trials, translation
Learn what good localisation looks like in clinical trials and why participant-facing materials should feel naturally relevant, culturally appropriate and easy to understand across every …